Clinical Trial Videos
Videos from past meetings

Many cancer patients feel that the clinical trial process is in need of a serious makeover. One of them is Jim Omel. Jim, a retired oncologist Iiving with multiple myeloma, turned patient advocate, makes it his business to understand myeloma from the inside out. He joins this program to share his experience in clinical trials and how he learned about his vulnerabilities as a cancer patient.
Also joining the discussion is, Dr. Michael Thompson, medical director for the Early Phase Cancer Research Program at the Aurora Research Institute and an active clinical researcher developing new treatments, particularly early phase (Phase I and II) molecular biomarker-driven clinical trials.
Join us for a meeting of the minds on debunking myths around clinical trials. How are patients protected within a trial? Will I as a patient be lost in the clinical trial system? Can I select my own arm in a trial? The questions are endless and, left unanswered, contribute to the barriers to trial enrollment.
Cast: Patient Empowerment Network
Tags: clinica trials, clinical trial, Clinical Trial Mythbusters and patient advocate
Interviews With KOLs and POLs About Clinical Trials

Interview with Patient Advocate, Lynette and Robert Orlowski, MD, PhD, Director of Myeloma and Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics The University of Texas MD Anderson Cancer Center
Cast: Patient Empowerment Network
Tags: Myeloma, Virtual Town Meeting, MD Anderson Cancer Center, Dr. Robert Orlowski, patient advocate and cancer patient

Janet Freeman-Daily interviews a panel of lung cancer experts about who is eligible for clinical trials and how you can learn more about them.
Cast: Patient Empowerment Network
Tags: lung cancer experts, lung cancer, Lung Cancer Town Meeting, panel interview, clinical trials and lung cancer clinical trials

Carol Preston interviews Dr. Andrew Zelenetz from Memorial Sloan Kettering in New York City about the recently presented results of the randomized, double-blind, placebo-controlled study of idelalisib in combination with Bendamustine and Rituximab for previously treated chronic lymphocytic leukemia. This trial asked the question, Could we take a standard of care treatment, that is, Bendamustine and Rituximab, a well-recognized standard of care, and improve upon it by the addition of idelalisib. This trial showed overwhelmingly positive results.
Cast: Patient Empowerment Network
Tags: ASH 2015, CLL, Clinical Trials, Chronic Lymphocytic Leukemia, Zelenetz and idelalisib

Patient Advocate, Vocille "Peppe" Fryou, shares her cancer journey. Even with 10 years without a diagnosis and several clinical trials, Peppe has persevered and has high hopes for the future.